Investigational Drug Information for Brequinar
✉ Email this page to a colleague
What is the drug development status for Brequinar?
Brequinar is an investigational drug.
There have been 4 clinical trials for Brequinar.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 19th 2020.
The most common disease conditions in clinical trials are COVID-19, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Clear Creek Bio, Inc. and [disabled in preview].
There are five hundred and seventy-six US patents protecting this investigational drug and zero international patents.
Summary for Brequinar
| US Patents | 576 |
| International Patents | 10,308 |
| US Patent Applications | 3,580 |
| WIPO Patent Applications | 1,595 |
| Japanese Patent Applications | 316 |
| Clinical Trial Progress | Phase 2 (2020-11-19) |
| Vendors | 61 |
Recent Clinical Trials for Brequinar
| Title | Sponsor | Phase |
|---|---|---|
| Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection. | Clear Creek Bio, Inc. | Phase 2 |
| CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 | Clear Creek Bio, Inc. | Phase 2 |
| Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19 | Clear Creek Bio, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for Brequinar
Top disease conditions for Brequinar
Top clinical trial sponsors for Brequinar
US Patents for Brequinar
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Brequinar | ⤷ Sign Up | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | ⤷ Sign Up |
| Brequinar | ⤷ Sign Up | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | ⤷ Sign Up |
| Brequinar | ⤷ Sign Up | Compositions and methods including celecoxib and plumbagin relating to treatment of cancer | The Penn State Research Foundation (University Park, PA) | ⤷ Sign Up |
| Brequinar | ⤷ Sign Up | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | ⤷ Sign Up |
| Brequinar | ⤷ Sign Up | Constructs targeting AFP peptide/MHC complexes and uses thereof | EUREKA THERAPEUTICS, INC. (Emeryville, CA) | ⤷ Sign Up |
| Brequinar | ⤷ Sign Up | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]- pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy | Oncoceutics, Inc. (Philadelphia, PA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Brequinar
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Brequinar | Australia | AU2011210567 | 2030-01-29 | ⤷ Sign Up |
| Brequinar | Canada | CA2787784 | 2030-01-29 | ⤷ Sign Up |
| Brequinar | European Patent Office | EP2528893 | 2030-01-29 | ⤷ Sign Up |
| Brequinar | European Patent Office | EP3138838 | 2030-01-29 | ⤷ Sign Up |
| Brequinar | Japan | JP2013518816 | 2030-01-29 | ⤷ Sign Up |
| Brequinar | Japan | JP2016183175 | 2030-01-29 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
